Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2024-205230

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Jonas Matthias Jabs, Viola Poeschel, MD, Martin Sökler, MD, Kerstin Habersang, MD, Rolf Mahlberg, MD, Ulrich Keller, Professor Dr, Heinz-Gert Hoeffkes, Professor Dr, Andreas Rank, PD Dr, Andreas Viardot, Professor Dr, Andreas Neubauer, Professor Dr, Marita Ziepert, PhD, Bettina Altmann, PhD, Stephan Stilgenbauer, MD, Michael Pfreundschuh, Professor Dr, Gerhard Held, Professor Dr, Joerg Thomas Bittenbring, MD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134944

Published: 2020

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Norbert Schmitz, MD PhD, Maike Nickelsen, MD, Marita Ziepert, PhD, Mathias Haenel, MD, Andreas Viardot, MD, Martin H. Dreyling, MD PhD, Peter Borchmann, MD, Carsten Bokemeyer, MD, Christian Peschel, MD, Hans-Heinrich Wolf, MD, Rolf Mahlberg, MD, Michael Pfreundschuh, MD, Bertram Glass, MD

Blood (2015) 126 (23): 474.

https://doi.org/10.1182/blood.V126.23.474.474

Published: 2015

Journal Articles

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Niels Murawski, Gerhard Held, Marita Ziepert, Barbara Kempf, Andreas Viardot, Mathias Hänel, Mathias Witzens-Harig, Rolf Mahlberg, Christian Rübe, Jochen Fleckenstein, Carsten Zwick, Bertram Glass, Norbert Schmitz, Samira Zeynalova, Michael Pfreundschuh

Blood (2014) 124 (5): 720–728.

https://doi.org/10.1182/blood-2013-10-535021

Published: 2014

Includes: Supplemental data

Journal Articles

Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission.

Blood (2006) 108 (11): 3141.

https://doi.org/10.1182/blood.V108.11.3141.3141

Published: 2006

Journal Articles

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Urban J. Scheuring, Patrick Brück, Matthias Stelljes, Rainer Schwerdtfeger, Nadezda Basara, Jolanta Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2005) 106 (2): 458–463.

https://doi.org/10.1182/blood-2004-05-1746

Published: 2005

Includes: Supplemental data

NARROW

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission.

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only